Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis

Aryl hydrocarbon receptor (AhR) agonist therapy for pediatric atopic dermatitis (AD) has shown much promise for addressing current treatment challenges with 1) efficacy in reducing atopic lesions and itching, 2) a rapid onset of action, and 3) improvement in quality of life without the safety concerns of steroids with long-term use. It is imperative that clinicians who treat pediatric patients with AD are familiar with AhR as a clinical target, including how targeting AhR affects mechanisms of atopic disease, and the clinical efficacy and safety data for AhR-directed therapies in pediatric AD to capitalize on their treatment benefits as they become available.

This educational activity, originally presented live at the 32nd Annual Master's of Pediatric Dermatology 2024 conference, will allow clinicians who were unable to attend the live symposium to benefit from the latest clinical evidence, medical animation detailing the disease and therapeutic mechanisms, and expert discussion of common challenges and lingering questions from providers who treat pediatric AD.

Target Audience

This activity is designed for an audience of US-based physicians, nurses and allied health providers (nurse practitioners and physician assistants) of dermatology practices that treat pediatric and adolescent patients.

Learning Objectives

Upon completion of the educational activity, participants should be better able to:

  • Describe the role of AhR in the pathogenesis of AD and the rationale for AhR as a clinical target.
  • Summarize the mechanisms of AhR-directed therapies and how the therapeutic effects differ from other drug classes.
  • Assess available data for emerging AhR-directed therapies in pediatric AD including clinical efficacy and safety and comparison studies.
Course summary
Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 
  • Role of AhR in Pediatric AD
  • AhR Agonist Mechanism of Action
  • Emerging AhR Agonists for AD
  • Expert Panel Discussion

Adelaide A. Hebert, MD
Professor of Dermatology and Pediatrics
UTHealth McGovern Medical School
Houston, Texas

Peter A. Lio, MD 
Clinical Assistant Professor of 
Dermatology & Pediatrics
Northwestern University Feinberg
School of Medicine
Chicago, Illinois

Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
University of Washington School of Medicine
Division Head, Dermatology
Seattle Children’s Hospital
Seattle, Washington


This activity is provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm.

Advancing Knowledge in Healthcare Inc.LiVDerm logo

Joint Accredited Provider Logo In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


1 ANCC contact hour.

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 31, 2025. PAs should only claim credit commensurate with the extent of their participation.


Commercial Support

This activity is supported by an educational grant from Dermavant Sciences, Inc.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.





Commercial Interest

Adelaide Hebert, MD


Pfizer,Arcutis, Dermavant, Incyte, Almirall, Galderma, Verrica, Novan


Pfizer, Arcutis, Dermavant, Incyte, Almirall, Galderma, Verrica


Pfizer, Arcutis, Dermavant, Novan

Peter A. Lio, MD


Alphyn Biologics, AbbVie, Almirall, Amyris, Arcutis, ASLAN, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Janssen, Johnson & Johnson, Kimberly Clark, LEO Pharma, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Suneco Technologies, Theraplex, UCB, Unilever, Verdant Scientific, Verrica, Yobee Care

Individual stocks and stock options

Codex Labs, Concerto Biosci, Suneco Technologies, Yobee Care, Verdant Scientific All are stock OPTIONS only NONE have initiated FDA contact at this time

Royalties or patent beneficiary

Theraplex AIM


AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica

Robert Sidbury, MD




Regeneron; Galderma; Castle; UCB; Pfizer

Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations


Nothing to disclose

Michele Bielarski, RN (planner/reviewer)


Nothing to disclose

AKH Inc Staff and Planners


Nothing to disclose

Tarsus dba LiVDerm Staff and Planners


Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.



This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.

AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.